Dasatinib is an oral oncology support medication classified as a tyrosine kinase inhibitor. It is supplied in a 50 mg strength packaged in a bottle. In Hong Kong, dasatinib is a prescription-only product regulated by the Department of Health. The drug targets specific enzymes involved in the growth of certain blood cancers, most notably chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL).
Dasatinib blocks the activity of several tyrosine kinases, the most important being BCR-ABL, a fusion protein that drives uncontrolled cell proliferation in CML and Ph⁺ ALL. By binding to the ATP-binding site of BCR-ABL, dasatinib prevents the enzyme from phosphorylating downstream proteins, thereby halting malignant cell growth. It also inhibits Src family kinases, which contributes to its broader anti-cancer activity.
In Hong Kong, dasatinib is approved for the following indications:
These approvals are based on extensive clinical trials demonstrating efficacy in achieving hematologic and cytogenetic responses. The drug is usually prescribed for adults, although pediatric dosing may be considered in specialized centers.
Some clinical studies have explored dasatinib in other hematologic malignancies, such as chronic lymphocytic leukemia (CLL) and certain myeloproliferative neoplasms. These investigations remain investigational, and dasatinib is not approved for these conditions by the Hong Kong Department of Health.
Off-label use requires medical supervision and individualized risk assessment.
Dosing must always be individualized by a qualified oncology specialist.
This article provides educational information about dasatinib and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Dasatinib absorption can be reduced by antacids, proton-pump inhibitors, and H₂-blockers if taken within two hours of the dose. Separate administration by at least two hours to maintain efficacy.
Report symptoms such as shortness of breath or chest discomfort promptly. The physician may pause treatment, start diuretics, or switch to an alternative therapy based on severity.
Patients with mild hepatic impairment may require dose adjustment. Severe liver dysfunction is an absolute contraindication. Liver function tests should be monitored regularly.
Dasatinib inhibits a broader range of kinases, including Src family members, which can provide activity against some dasatinib-resistant BCR-ABL mutations. Specific comparative efficacy depends on individual patient profiles.
No. Dasatinib is classified as pregnancy Category D and can cause fetal harm. Effective contraception is required for women of childbearing potential.
Store at room temperature, keep the bottle tightly closed, and protect from moisture and heat. Do not refrigerate or expose to direct sunlight.
Grapefruit juice can inhibit CYP3A4, potentially increasing dasatinib blood levels and risk of toxicity. It is advisable to avoid large amounts of grapefruit products.
Initially, weekly CBC monitoring is recommended, followed by every 2-4 weeks once stable, to detect myelosuppression early.
Yes, dasatinib is marketed as a generic drug in Hong Kong, supplied in 50 mg tablets. Availability may vary between pharmacies.
Carry the medication in its original packaging, keep it in your carry-on luggage, and bring a copy of the prescription. Inform security personnel if questioned, and maintain a stable temperature during the journey.
